Project Grant R01HL178410
Award Date
7/5/25
Completion Date
4/30/30
Dollars Obligated
$620K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Michigan, USA
Similar Awards
This federal Project Grant award of $246,776.00 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to develop novel methods for creating and validating polygenic scores (PS) that can predict medication response in African American populations. The goal is to create ancestry-robust PS tools that account for local genetic ancestry context, improving their predictive performance for non-European populations. The...
The federal Project Grant award R01HL176882, totaling $734,722.00, was provided by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to the University of Alabama at Birmingham (UAB). The award will fund a randomized clinical trial to assess the efficacy of disseminating systolic blood pressure polygenic risk scores (SBP PRS) on SBP control, adherence to a healthy lifestyle, and cardiometabolic profile among 300 hypertensive young and middle-aged U.S....
This Project Grant award of $194,400 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports the development of a multilevel implementation intervention to equitably prescribe evidence-based therapy for hospitalized heart failure patients. The key products or services to be delivered through this funding include: Assessing multilevel variation in equitable guideline-directed medical therapy (GDMT) prescribing during...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), funded under the Cardiovascular Diseases Research program (CFDA 93.837), will support a $198,936 research project conducted by New York University School of Medicine. The project aims to investigate the impact of restrictive drug coverage policies, such as cost-sharing and prior authorization requirements, on prescribing patterns, medication adherence, and clinical outcomes for patients with heart failure with...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,706,807 to the Regents of the University of Michigan to conduct research on small-molecule effectors targeting cardiac ion pumps. The overarching goals are to determine the mechanisms underlying small-molecule activation of the cardiac calcium pump (SERCA) and to discover new classes of small-molecule inhibitors of the cardiac sodium pump (NKA). These...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, provides $1,135,350 to the Regents of the University of Michigan to conduct research on the genetic causes of primary aldosteronism (PA) in Black Americans. The key objectives are: 1) to define the spectrum of aldosterone-driver PA somatic mutations in Black American patients, and 2) to identify targeted therapeutics that block mutation-driven...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $165,364 to The Broad Institute, Inc. to conduct research focused on integrating novel contextual and genomic blood pressure measures to enhance cardiovascular disease prediction and management in young adults aged 18-39 years. The key objectives of this 2-year project are to: 1) identify novel ambulatory blood pressure patterns that capture dynamic responses to...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $429,153 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Michigan Technological University. The funding supports research to improve patient selection and left ventricular lead placement for cardiac resynchronization therapy (CRT) by integrating analysis of electrical dyssynchrony on ECG and mechanical dyssynchrony on gated SPECT myocardial perfusion imaging. The project aims to use unsupervised...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $167,400 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Regents of the University of Michigan. The 5-year grant, which commenced on May 15, 2025, supports research by Dr. Joshua Meisner, a pediatric cardiologist and physician-scientist, to elucidate the mechanical and metabolic pathways underlying hypertrophic cardiomyopathy (HCM) caused by MYBPC3 gene mutations. The research aims to develop...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $699,133 in funding to the University of California, Los Angeles (UCLA) to conduct research on the epigenetic regulation of heart failure with preserved ejection fraction (HFPEF). The key goals are to reveal molecular insights into the actions of SGLT2 inhibitor and GLP1 agonist drugs across multiple organs, identify novel...